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UbiquitinationThe serine threonine kinase AKT plays a central role in the regulation of cell survival in a variety of human
neoplastic diseases. A series of studies have revealed a connection between AKT signaling and two important
protein degradation pathways in mammalian cells: the ubiquitin–proteasome system and autophagy. Two
distinct ubiquitination systems have been reported to regulate AKT signaling: K63-linked ubiquitination,
which promotes the oncogenic activation of AKT, and K48-linked ubiquitination, which triggers the proteasomal
degradation of phosphorylated AKT. Autophagy is an evolutionarily conserved mechanism for the gross disposal
and recycling of intracellular proteins inmammalian cells. AKT signalingmay play a regulatory role in autophagy;
however, the underlying mechanisms have not been fully clariﬁed. Recently, AKT was shown to phosphorylate
key molecules involved in the regulation of autophagy. Furthermore, lysosomal co-localization of the AKT–
Phaﬁn2 complex is reportedly critical for the induction of autophagy. In this review, we will discuss the
connection between AKT, a core intracellular survival regulator, and twomajor intracellular proteolytic signaling
pathways in mammalian cells.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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The serine threonine kinase AKT, also called protein kinase B (PKB),
regulates a range of cellular processes, including cell survival, cell cycle
progression, cytoskeletal organization, vesicle trafﬁcking, glucose trans-
port, and platelet function. Deregulation or malfunction of AKT contrib-
utes to a wide variety of human diseases including cancers, glucose
intolerance, schizophrenia, viral infections, and autoimmune diseases
[1–3]. Two major proteolytic pathways are present in mammalian
cells: autophagy and the ubiquitin–proteasome system [4–6]. A series
of studies has shown that the PI3K (phosphoinositide 3-kinase) –AKT–
mTOR (mammalian target of rapamycin) pathway, which mediates
anti-apoptotic signaling, may play an important role in the regulation
of autophagy and the ubiquitin-proteasomal system in mammalian
cells [7–13].
Ubiquitin was originally proposed to deliver tagged proteins to the
cellular waste disposal machinery via the 26S proteasome. Ubiquitin, a
76-residue protein, is covalently associatedwithprotein substrates. Pro-
tein ubiquitination is mediated by the concerted action of essentially
three enzyme families (E1, E2, and E3). Ubiquitin is activated ﬁrst by a
ubiquitin-activating enzyme (E1) through an ATP-dependent reaction
to form an E1-thioesterlinkage, and the activated ubiquitin is trans-
ferred to a member of the ubiquitin-conjugating enzyme E2 family. AFig. 1. Two distinct ubiquitination systems regulate AKT and downstream cellular response
membrane, which is important for oncogenic AKT activation. NEDD4 catalyzes K63-linked u
ubiquitination of AKT by TTC3, CHIP, or MULAN, or BRCA1 promotes proteasomal degradation. P
for the activation of AKT and downstream responses such as proliferation and tumorigenesis. In
triggers proteasomal degradation. MULAN- and CHIP-mediated ubiquitination likely to occu
ubiquitination and deubiquitination.ubiquitin–protein ligase (E3) then mediates the transfer of ubiquitin
from E2 to the substrate protein by promoting the formation of an
isopeptide bond between the ubiquitin (Ub) carboxyl-terminus and
speciﬁc lysine side chains on the substrate [14,15]. In the human ge-
nome, there are over 500 genes that appear to be E3 ligases, and there
are potentially over 1500 molecules that can be targeted by ubiquitin
and/or ubiquitin like proteinmodiﬁcations [16]. E3 ligases can generally
be classiﬁed into two families: RING (really interesting new gene) type
E3 ligases, and HECT (homologous to the E6-associated protein C termi-
nus) type E3 ligases. The activity of the ubiquitin system is dependent
on the speciﬁcity of the E3 ubiquitin ligases [17].
In addition to its control of protein turnover, protein ubiquitination
of protein has an additional impact on various cellular functions, includ-
ing facilitation of cell-surface-receptor turnover and control of gene
transcription [15].
Two distinct ubiquitination systems for AKT have been reported:
K63-linked ubiquitination of lysine of ubiquitin by TRAF6 (tumor necro-
sis receptor-associated factor 6) [18], Skp2 (SKP1 interacting partner 2)
[12], or NEDD4 (neural precursor cell expressed developmentally
down-regulated protein 4) [19], induces AKT activation by promoting
plasma membrane translocation and/or nuclear translocation. In con-
trast, K48-linked ubiquitination of lysine of ubiquitin by BRCA1 (breast
cancer susceptibility gene 1) [8], MULAN (mitochondrial ubiquitins. K63-linked ubiquitination by TRAF6/Skp2 induces the translocation of AKT to the plasma
biquitination of phosphorylated AKT to promote its nuclear translocation. K48-linked
IAS1-mediated SUMOlylation of AKT, which occurs mainly in the nucleus, is also essential
contrast, K48-linked ubiquitinationmediated by BRCA1 or TTC3 occurs in the nucleus and
rs in the cytosol. Moreover, the CYLD deubiquitinase controls the balance between AKT
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ligase) [20], and TTC3 (tetratricopeptide repeat domain 3) promotes
the proteasomal degradation of AKT [9], likely in order to silence AKT
kinase activity (Fig. 1).
Autophagy is an evolutionally conserved homeostatic process for
intracellular degradation by which intracellular proteins are seques-
tered in a double-membrane-bound autophagosome and delivered
to the lysosome during stress conditions; this process facilitates bothFig. 2. The PI3K–AKT–mTOR pathway and the induction of autophagy. The PI3K–AKT–m
suppresses catabolic processes such as autophagy. Pharmacological PI3K inhibitors such as wo
potent inducer of autophagy. In addition to acting as a trafﬁc nutrient transporter, mTORC1 s
TRAF6-mediated K63-linked ubiquitination of mTORC1 is important for its translocation to lyso
in the regulation of autophagy. Casein kinase II, a kinase upstream of AKT that localizes to the G
proteins. FOXO3, ULK1 (ATG1), and Beclin1 (ATG6) control autophagy as direct substrates of AK
is essential for autophagy underscores the signiﬁcance of the AKT–mTOR axis in regulation ofdegradation and recycling in mammalian cells. The molecular machin-
ery of autophagy co-ordinates diverse aspects of cellular and organismal
responses to other dangerous stimuli such as infection [21,22]. There-
fore, defective autophagy underlies a wide variety of human disease
and physiology including cancer, neurodegeneration, and infectious
diseases [5,23,24]. The three best characterized forms of autophagy
are chaperon-mediated autophagy, microautophagy, and macroauto-
phagy. Macroautophagy, which was originally referred to simply asTOR pathway plays an important role in the regulation of autophagy. Activation of AKT
rtmannin or 3-MA inhibit autophagy. In contrast, rapamycin, which inhibits mTORC1, is a
ignals to the ULK1/ULK2 and Beclin1 complexes to promote autophagosome formation.
somes and the activation of autophagy. In addition to mTORC1, AKT may also be involved
olgi/lysosome, phosphorylates p62 to promote the autophagic clearance of ubiquitinated
T. The ﬁnding that translocation of AKT–Phaﬁn2 and p62–TRAF6–mTORC1 to the lysosome
the process.
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membrane encapsulated autophagosome; these structures are then
fused with lysosomes for degradation, organelle turn-over, and recycling
of proteins.Macroautophagy can be both selective andnon-selective, and
can be subdivided into several subcategories (i.e., mitophagy, ribophagy,
or aggrephagy). Recent studies indicate that selective autophagy is also
mediated through ubiquitination [25,26]. The role of ubiquitination in se-
lective autophagy provides further evidence of the connection between
ubiquitination and autophagy [25,26].
Studies with pharmacological inhibitors suggest that AKT can regu-
late autophagy [11]. Although the underlying molecular mechanisms
are not fully understood, it is clear that ULK1 (Unc-51 like autophagy ac-
tivating kinase 1, ATG1) and beclin1 (ATG6), two key regulators of au-
tophagy, are substrates for AKT-dependent phosphorylation [11,27]. In
addition, AKT is shown to bind to Phaﬁn2 in order to be re-localized to
the lysosome during autophagy induction [28]. Furthermore, TRAF6-
mediated ubiquitination of p62, an autophagy receptor for ubiquitinated
proteins, which is critical for the regulation of apoptosis and autophagy,
is important for the lysosomal localization of mTOR, a major down-
stream effector of AKT that regulates autophagy [29–31] (Fig. 2).
In this review,we summarize the current state of knowledge regard-
ing ubiquitination of AKT and the role of AKT in autophagy. We place
this in the context of the two major cellular proteolytic pathways in
order to highlight the importance of this signaling network, in particular
as regards human diseases.
2. AKT signaling and ubiquitination
AKT belongs to the AGC family of kinases [1,32,33] and contains a
pleckstrin homology (PH) domain at its N-terminus. The AKT-PH
domain is an electrostatically polarized domain that adopts the same
fold and topology as other PH-domains, which consist of a seven-
stranded β-sandwich capped by an α-helix [32].
In response to growth factors and other extra-cellular stimuli, AKT
is activated by the lipid products [PtdIns (3,4,5)P3 and its immediate
breakdown product PtdIns (3,4)P2] of phosphoinositide 3′-kinase
(PI3K), which phosphorylates the 3-OH position of the inositol core of
inositol phospholipids (PtdIns) [34–36]. Structural studies reveal that
the binding pocket of PtdIns (1,3,4,5)P4 [the polar head group of PtdIns
(3,4,5)P3] is within variable loop 1 (VL1, the loop between the β1 and
β2 strands) of the AKT PH domain [37–40].
Three AKT isoforms have been identiﬁed in the human genome
(AKT1, AKT2, and AKT3). These isoforms share a highly conserved PH-
domain, which binds to PI(3,4,5)P3. The interaction is critical for the
translocation of AKT to the plasma membrane. Under physiological
conditions, AKT1 and AKT2 are ubiquitously expressed, whereas AKT3
expression is restricted, predominantly to heart, kidney, brain, testis,
lung, and skeletal muscle [1–3,41]. It is clear that AKT plays a central
role in regulating cell survival. AKT phosphorylates the pro-apoptotic
BAD protein, which enhance the association of BAD with 14-3-3 pro-
teins. This effectively blocks the death-inducing function of BAD, since
it is then unable to interact with and antagonize the anti-apoptotic
protein Bcl-2. AKT also activates the IκB (nuclear factor of kappa light
polypeptide gene enhancer in B-cells inhibitor)/NFκB (nuclear factor-
kappa B) transcription factor complex by inducing the proteasomal
degradation of IκB to inhibit apoptosis. AKT also induces phosphoryla-
tion of the FOXO/forkhead family of transcription factors and, con-
sequently, reduces cellular levels of p27Kip1. Other AKT substrates
include GSK (glycogen synthase kinase), CREB (cyclic AMP response-
element binding protein), XIAP (X-linked inhibitor of apoptosis
protein), Nur77, p27Kip1, MDM2 (murine double minute 2), eNos (en-
dothelial nitric oxide synthase), andWEE1Hu (Wee-like protein kinase)
[3]. Due to the diverse roles of AKT as outlined above, deregulation or
malfunction of AKT is associated with many human diseases, including
cancer, glucose intolerance, schizophrenia, viral infections, and auto-
immune disorders [1–3,42].Activation of the AKT isoforms-1, -2, and -3 is regulated by phos-
phorylation at two regulatory sites: threonine 308/309/305, which are
targeted by PDK1 (phosphoinositide-dependent kinase-1) and serine
473/474/472 which are targeted by the ribosome-associated Rictor–
mTOR complex (mTORC2, mammalian target of rapamycin complex
2) [1–3,33,42–45]. Phosphorylation of both these sites is required for
maximum kinase activity [1–3,42]. In line with other kinases, the activ-
ity of AKT is clearly regulated by both phosphorylation and dephosphor-
ylation [1–3,42]. However, kinases are also targets of ubiquitination and
ubiquitin-like modiﬁcations, including SUMOylation [16,46–48]. Con-
sistent with this AKT kinase activity can be modiﬁed by both lysine 48
(K48)-linked polyubiquitination and lysine 63(K63)-linked poly-
ubiquitination [4,48]. K48-linked ubiquitination is thought to control
proteasomal degradation of AKT, thereby effectively shutting off AKT
activity and downstream responses. In contrast, K63-linked poly-
ubiquitination is thought to serve as a regulatory signal that promotes
plasma membrane recruitment of AKT [47–49]. The diversity of the
biological actions that can be controlled by ubiquitination/deubiqui-
tination is due to both the high substrate speciﬁcity of the ubiquitin sys-
tem and the variety of regulatory mechanisms that control the activity
of both ligases and deubiquitinases [16,49–52].3. K48-linked ubiquitination of AKT
TTC3 (tetratricopeptide repeat domain 3), an E3 ubiquitin ligase,
was identiﬁed as an AKT binding partner through a yeast two-hybrid
screen. TTC3 contains an H2-RING ﬁnger domain, AKT phosphorylation
motifs (TPRSLSAP), tetratricopeptide repeat (TPR) motifs, and two nu-
clear localization signals [9]. Several lines of evidence indicate that
phosphorylation plays a key role in regulating the function of E3 ligases
[53]. The interaction of an E3 ligase with a substrate, which is regulated
by post-translational modiﬁcation such as phosphorylation, provides
substrate speciﬁcity [53]. Indeed, both in vitro and in a cellular context,
AKT induces phosphorylation of TTC3 at Ser378. This phosphorylation is
an important prerequisite step for AKT ubiquitination. In mammalian
cells, TTC3 interacts preferentially with phosphorylated AKT at Thr308
to induce the polyubiquitination and subsequent degradation of AKT.
Phosphorylation of TTC3 at Ser378 is required for ubiquitination and
proteasomal degradation of AKT and its downstream biological re-
sponses [9].
The breast cancer susceptibility gene 1 (BRCA1) plays a key role in
mammary tumorigenesis. The BRCA1–BRCT (Brca1 C-terminal) domain
binds to phospho-T308 and phospho-S473 AKT and triggers their K48-
linked ubiquitination and degradation, presumably in the nucleus.
This suggests that BRCA1 is a negative regulator of the AKT pathway
and emphasizes the signiﬁcance of the BRCA1/AKT pathway in tumori-
genesis [8]. AKT is also ubiquitinated and negatively regulated by the
mitochondrial protein MULAN, an E3 ligase, possibly in the cytosol.
MULAN preferentially interacts with and mediates the ubiquitination
of phosphorylated AKT, thereby promoting AKT degradation, which
suppresses cell proliferation and viability [10]. However, whether
MULAN preferentially ubiquitinates phospho-T308 or phospho-S473
was not speciﬁed in the study [10].
Furthermore, Hsp90 (heat shock protein 90) reportedly interacts
with and stabilizes AKT [54]. CHIP (chaperone-associated ubiquitin li-
gase), one of the E3 ligases that harbors a TPR (tetratricopeptide repeat)
motif, was shown to interact with Hsp90 and control the ubiquitination
of AKT [20,55]. CHIP co-regulates the degradation of the Alzheimer's
disease-related protein, tau through coordinated interactions. This like-
ly involves AKT, since AKT regulates both tau kinase activity and protein
quality control, thus linking several common pathways that contribute
to dysfunction in Alzheimer's disease [20]. Since TTC3 also induces
proteasomal degradation of phospho-AKT, there may be a pathogenic
connection between the TTC3–AKT–eNOS axis and the neurological
symptoms of Down syndrome [9]. However, a direct involvement of
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demonstrated.
Interestingly, K48-linked ubiquitination of AKT occurs both in the
cytosol (MULAN and CHIP) and in the nucleus (BRCA1 and TTC3)
[8–10,20,55]. Because AKT has nuclear (FOXO, Nur77) and cytosolic
substrates (BAD, GSK), AKT ubiquitination and proteasomal degrada-
tion may differentially affect the phosphorylation of nuclear and cyto-
solic substrates, thereby controlling the various cellular responses
regulated by AKT. However, how these different ubiquitin ligases differ-
entially regulate the AKT is currently unknown and clariﬁcation re-
quires further study.
It is noteworthy that unlike phosphorylation of AKT, ubiquitination
of AKT has multiple effects in other aspect of enzymatic action.
Ubiquitin-dependent AKT degradation is prevented by a translation-
coupled phosphorylation event at Thr450 mediated by mTORC2 in a
growth factor independent manner. Thus, phosphorylation of AKT at
the Turn motif (TM) by mTORC2 in a growth factor independent man-
ner is also reported to control the stability of AKT [56].
4. K63-linked ubiquitination and AKT kinase activation
Ubiquitination also has proteasome-independent functions in endo-
cytosis and signaling. Unlike K48-linked ubiquitination, which signals
for proteasomal degradation, K63-linked polyubiquitin chains are
thought to serve as a regulatory signal and to provide a scaffold for
the assembly of protein kinase complexes [47–49]. TRAF6, HectH9, c-
IAP1/2 (inhibitors of apoptosis 1/2), and RNF8 (ring ﬁnger protein 8)
are all known to mediate K63-linked ubiquitination [57–60].
AKT resides primarily in the cytosol and nucleus. Upon growth factor
stimulation, PI3K catalyzes the production of PI(3,4,5)P3 at the plasma
membrane. The PH-domain of AKT binds PI(3,4,5)P3 with high afﬁnity.
However, the molecular mechanisms involved in the translocation of
AKT to the plasma membrane and its subsequent activation by PDK1
ormTORC2 are not fully understood. TRAF6, amember of the tumor ne-
crosis factor receptor-associated factor family [61], was shown to pro-
mote AKT activation through K63-linked ubiquitination [11] (Fig. 1).
In response to insulin-like growth-factor stimulation (IGF-1), TRAF6
ubiquitinates the PH-domain of AKT, which promotes AKT membrane
recruitment and phosphorylation. Sequence alignment identiﬁed K8
and K14 within the PH-domain of AKT as the primary sites for K63-
linked ubiquitination. K63-linked ubiquitination of AKTpromotes trans-
location of AKT to the plasmamembrane, where it is phosphorylated by
PDK1 and mTORC2 at Thr308 and Ser473, respectively. Ubiquitination
does not affect the binding of AKT to PI(3,4,5)P3, butmay cause a confor-
mational change that enables AKT to interact with a putative protein
that transports the kinase to the plasma membrane. In addition,
TRAF6 acts not only upstream of mTORC1 through p62 during nutrient
sensing but also downstream of mTORC1 through the AKT–TSC (tuber-
ous sclerosis complex) axis in response to insulin and growth factors.
TRAF6−/−mice exhibit thymic atrophy and disorganogenesis, suggest-
ing that TRAF6-mediated AKT activation primarily affects the immune
system [62]. Therefore, blocking TRAF6 may have therapeutic potential
in cancer especially in the immune systems.We note, however, that the
E3 ubiquitin ligase TRAF6 does not always activate AKT kinase activi-
ty [63,64]. TRAF6 inhibits LPS-induced AKT activation in FLT3-ITD-
positive MV4-11 AML cells [63]. Activation of the PI3K–AKT pathway
is higher in TRAF6-deﬁcient T cells [64]. Consistently, levels of basal
phosphorylation of GSK3β are higher in TRAF6 knock down cells [65].
Thus, TRAF6 expression may affect AKT phosphorylation differently in
a various cellular environments.
There is also evidence that SCF E3 ligase (Skp2, E3 ligase S-phase ki-
nase associated protein 2)mediates EGF (epidermal growth factor) sig-
naling toAKT via K63-linked ubiquitination [12]. In contrast to TRAF6 E3
ligase, which orchestrates IGF-1-induced AKTubiquitination and activa-
tion [11], the Skp2 SCF complexmediates AKT ubiquitination andmem-
brane recruitment in response to the activation of ErbB receptors byEGF. Furthermore, Skp2 overexpression correlates with AKT activation
and breast cancer metastasis [12]. Ubiquitination of AKT by Skp2 or
TRAF6, each of which promotes the membrane recruitment of AKT for
the subsequent activation, is extracellular growth factor dependent:
EGF for Skp2 and IGF for TRAF6, respectively [11,12]. These observations
support amodel inwhich different growth factors use distinct E3 ligases
to activate AKT. Thus, depending on the context, either Skp2 or TRAF6
can catalyze K63-linked ubiquitination of AKT to control cellular
responses.
NEDD4-1(neural precursor cell expressed developmentally down-
regulated protein 4) reportedly catalyzes the attachment of K63-
linked polyubiquitin chain to AKT in vitro [19]. Thus, AKT joins PTEN
(phosphatase and tensin homolog deleted from chromosome 10) [66]
and ﬁbroblast growth factor receptor 1 (FGFR1) [67], as a substrate for
the NEDD4-1 E3 ligase. AKT ubiquitination byNEDD4-1 positively regu-
lates the nuclear trafﬁcking of the activated form of AKT (p-AKT).
Ubiquitinated p-AKT translocates to the perinuclear region, where it is
released into the cytoplasm, imported into the nucleus, or coupled to
the proteasome for degradation [19]. IGF-1 signaling stimulates the se-
lective ubiquitination of p-AKT (and not total AKT) by NEDD-4 [19]. The
AKT (E17K), a constitutively active and oncogenicmutant, ismore effec-
tively ubiquitinated by NEDD4-1 and hence more efﬁciently targeted to
the nucleus than that wild-type AKT, suggesting that AKT (E17K) is a
better substrate for E3 ligases [19] (Fig. 1).
K63-linked ubiquitination provides a molecular platform for pro-
tein–protein interactions involved in signaling activation, protein traf-
ﬁcking, and receptor endocytosis [47–49]. In this regard, it is possible
that K63-linked ubiquitination of AKT may increase its afﬁnity for
PAK1 (p21 protein-activated kinase 1) [68].5. Other ubiquitin modiﬁers involved in AKT signaling
Deubiquitinating enzymes (DUBs) cleave the peptide or isopeptide
bond between ubiquitin and a substrate protein to reverse the
ubiquitination reaction [48,69]. By removing ubiquitin from proteins,
DUBs regulate protein degradation, localization, activation, and interac-
tions. Recently, CYLD (cylindromatosis), whichwas originally identiﬁed
as deubiquitinating enzyme in the NF-κB pathway, was identiﬁed as a
DUB for AKT [70]. Studies of the CYLD knockout mouse and human
CYLD mutation in various human cancers indicate that CYLD is a
tumor suppressor [71,72]. CYLD interacts directly with AKT and
deubiquitinates it in response to growth factor stimulation, thereby
allowing E3 ligases back again to induce the ubiquitination and activa-
tion of AKT [70]. CYLDmay also remove K63-linked ubiquitin from acti-
vated AKT, which facilitates K48-linked-ubiquitination and degradation
by BRCA1 and/or TTC3. Thus, CYLD could act as a molecular switch for
theubiquitination anddeubiquitination of AKT,which in turnwould de-
termine its localization and activation during cancer progression [70]
(Fig. 1).
Ubiquitin and ubiquitin-like (Ubl) protein modiﬁcations affect
protein stability, activity, and localization, although the biological con-
sequences of these modiﬁcations are less well characterized in compar-
ison to ubiquitin [4,47–49]. In general, kinases are enriched among
ubiquitination targets [16]. However, another post-translationalmodiﬁ-
cation of AKT, SUMOylation at K273 by PIAS1 (protein inhibitor of acti-
vated STAT-1), has also been reported. PIAS1 SUMOylates and activates
AKT in the nucleus, although themechanism behind this is not yet fully
understood. However, SUMOylation of AKTmay be essential to activate
AKT, promote proliferation, and thereby enhance tumorigenic activi-
ty [73]. These observations together underscore the physiological signif-
icance of the ubiquitin systemwithin the context of the AKT–mTOR axis
(Fig. 1). Moreover, indirect involvement of ubiquitination of PI3K–AKT
signal is also known to modulate AKT signaling. Parkin, an E3 ligase im-
plicated in the pathogenesis of Parkinson's diseases, is shown to modu-
late the PI3K–AKT signaling through the ubiquitination and subsequent
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(EGFR) without directly interacting with AKT [74].6. PI3K–AKT–mTOR signaling is linked to autophagy
Growth factor stimulation activates PI3K (phosphoinositide 3-
kinase), a lipid kinase, which phosphorylates the 3′-OH group of the
inositol ring in inositol phospholipids. Three classes of PI3Ks (class IA,
IB, II, and III) are deﬁned by their distinct substrate preferences. Class I
PI3Ks are responsible for the production of phosphatidylinositol 3-
phosphate (PtdIns(3)P), phosphatidylinositol (3,4)-bisphosphate
(PI(3,4)P2), and phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)
P3. Class III PI3Ks produce PtdIns(3)P from PI by forming a heterodimer
with catalytic (Vps34) and regulatory (Vps15/p150) subunits [32,75].
The essential role of Vps34 (vacuolar protein sorting 34, a class III
PI3K) in autophagy has been established largely through the use of
the pharmacological inhibitors wortmannin and 3-methyladenine (3-
MA), which suppress autophagy [76–78]. A study of Vps34-null cells
demonstrated that this protein plays an essential role in autophagy in
the liver and heart [79]. In budding yeast and unicellular eukaryotes,
Vps34 regulates vesicle trafﬁcking [80]. In yeast, the nucleation and
assembly of the initial phagophore membrane requires Vps34, the
myristoylated serine/threonine kinase Vps15 (p150 in mammalian
cells), Atg14 (Barker or mAtg14 in mammalian cells), and Atg6/Vps30
(Beclin1 in mammalian cells) [81]. In multicellular organisms and
higher eukaryotes, a number of growth factor receptors activate the
catalytic p110 subunit of class IA PI3Ks (p110α/p110β, 110δ). In mam-
malian cells, Vps34 is also involved in nutrient signaling to mTOR [82].
The PI3K–AKT–mTOR pathway, which mediates anti-apoptotic sig-
naling,may play an important role in the regulation ofmacroautophagy,
the most prevalent form of autophagy in mammalian cells [26,83–85]
(Fig. 2). Pharmacological inhibitors of the PI3K–AKT–mTOR pathway
are known tomodulate the induction of autophagy. Pan-PI3K inhibitors,
such as wortmannin or LY294002, which is known to suppress the pro-
duction of both PtdIns(3)P and PI(3,4,5)P3, inhibit macroautophagy in
isolated rat hepatocytes [78]. By contrast, 3-MA (a class III PI3K inhibi-
tor), which speciﬁcally inhibits the production of PtdIns(3)P, is widely
utilized as an autophagy inhibitor [28,86]. Rapamycin, an mTORC1 in-
hibitor, is widely used to induce autophagy [87]. Class I PI3K products
block the autophagic pathway and distinct classes of PI3K are involved
in signaling pathways that control macroautophagy [77]. Inhibition of
PI3K or AKT synergistically sensitizes malignant glioma cells to rapa-
mycin [88]. These complexities are partly explained by the possibilities
of the cross inhibition of class I vs. class III PI3K products. A constitutive-
ly active form of AKT suppressed the induction of autophagy by
rapamycin, whereas dominant negative AKT promoted autophagy in-
duced by treatment with rapamycin and LY294002 [88]. Inhibition of
AKT synergistically sensitizes malignant cells to rapamycin, thus pro-
moting autophagy, and sensitizes PTEN-null tumors to lysotropic re-
agents [89].
Since activation of PI3K–AKT underlies the pathogenesis of vari-
ous cancers [1–3], it is imperative that we understand how modula-
tion of PI3K–AKT and the subsequent changes in autophagy might
affect cancer progression. Some lessonsmay come from observations
that-AKT activation is suggested to prevent the induction of autoph-
agy in order to preserve cell viability and promote normal cell
growth [7,13,90]. Activation of AKT potentiates anabolic processes,
including protein translation and cell growth, and suppresses cata-
bolic processes such as autophagy [13]. For example, constitutive
AKT activity inhibits the TSC complex; this leads to an increase in
Rheb, a small GTPase that activates mTORC1, and as a consequence,
suppresses autophagy. Furthermore, AKT suppresses the retrograde
degeneration of dopaminergic axons by inhibiting macroautophagy
[91]. Conversely, PTEN, a negative regulator of AKT, stimulates au-
tophagy [13,90] (Fig. 2).7. Lysosomal interaction of AKT with Phaﬁn2
Another investigation offers additional evidence of the involvement
of AKT in autophagy regulation. By yeast two-hybrid screening, Phaﬁn2
(EAPF or PLEKHF2), a lysosomal protein with a unique structure of N-
terminal PH domain and C-terminal FYVE (Fab 1, YOTB, Vac 1, and
EEA1) domain, was found to interact with AKT [28]. These conserved
motifs place Phaﬁn2 in a family of proteins known to induce caspase-
independent apoptosis via the lysosomal-mitochondrial pathway
[92]. Previously, Phaﬁn2 was suggested to control receptor trafﬁcking
through the endosome [93]. AKT translocates with Phaﬁn2 to the lyso-
some in a PtdIns(3)P-dependent manner after induction of autophagy.
Lysosomal accumulation of the AKT–Phaﬁn2 complex and subsequent
induction of autophagy are lysosomal PtdIns (3)P-dependent events,
and the formation of this complex at lysosome is a critical step in induc-
tion of autophagy via interaction with PtdIns (3)P [28]. These observa-
tions also suggest that the regulation of lysosomal localization of AKT
affects autophagy induction (Fig. 3).
Autophagy also implicated in tumor progression [5,23,24,94,95]. In
order to elucidate the role of Phaﬁn2 in the regulation of tumorigenesis,
we have examined whether Phaﬁn2 overexpression affects tumor
growth.
In this regard, our preliminary observations suggested that over-
expression of wild type Phaﬁn2, but not PtdIns(3)P interaction-
defective-Phaﬁn2, inhibited RAS-induced and TCL1-induced trans-
formation. Although precise mechanisms for the involvement of
autophagy in tumorigenesis remain to be clariﬁed in further studies,
these observations are consistent with the precedent reports that
regulation of autophagy is indeed involved in the tumor progression
[94,95].
PtdIns(3)P is highly enriched on early endosomes and in the internal
vesicles of multivesicular endosomes [96]. These ﬁndings clarify the
molecular mechanism by which cytosolic AKT translocates to the lyso-
some to phosphorylate its substrates and control autophagy induction.
3-MA, a widely utilized pharmacological inhibitor for autophagy, is
known to inhibit enzymatic action of class III PI3K activity, which sup-
presses production of PtdIns(3)P [77,87]. Using 3-MA, we showed that
PtdIns(3)P-dependent lysosomal translocation of the AKT–Phaﬁn2
complex was required for induction of autophagy [28].
Experiments in lower eukaryotes also support a role for AKT in au-
tophagy [6,97]. Based on structural similarities, the yeast Sch6 gene is
a candidate AKT ortholog [98–100]. In this regard, it has been suggested
that Sch9 kinasemay regulate autophagy in response to change in nutri-
ent availability [98,99]. Notably, both negative [101] and positive [102,
103] roles of the mTORC1 substrate S6K1 (p70 S6 kinase 1) in auto-
phagy have been reported.
The physiological roles of AKT in the regulation of autophagy are
further supported by experiments in mammalian cells [27,104]. ULK1
(ATG1), a serine threonine kinase related to UNC-51 kinase in Caenor-
habditis elegans, induces autophagy by phosphorylating Beclin1 and
activating Vps34 [104]. AKT phosphorylates ULK1 at Ser774 in vitro,
providing further support that AKT is involved in the regulation of
autophagy [27].
Furthermore, FOXO3, member of the O subclass of the forkhead
family of transcription factors, is an AKT substrate that regulates the
cell deathmachinery [105]. FoxO3 coordinately activates protein degra-
dation by the autophagic/lysosomal and proteasomal pathways in
atrophyingmuscle cells [106]. In hematopoietic stem cells under starva-
tion conditions, FOXO3 activity is required for induction of a gene
expression program that induces autophagy in order tomitigate the en-
ergy crisis and promote cell survival [107]. Because rapamycin cannot
induce autophagy in skeletal muscle, the cellular salvage pathway relies
more on AKT–FOXO signaling, rather than on the AKT–mTOR axis. In
this regard, it is of note that FOXO protein stability is regulated via
Skp2/MDM2-mediated-ubiquitination and proteasomal degradation
[108].
Fig. 3. Spatial control of AKT determines the fate of autophagy. In response to growth factor stimulation, class I PI3Ks produce PI(3,4,5)P3 at the plasma membrane. The PH-domain of
AKT interacts with PI(3,4,5)P3 to promote the translocation of AKT to the plasma membrane, where it is activated by PDK1 and/or mTORC2. Upon autophagy induction, class III PI3Ks
produce PtdIns(3)P at the lysosomal/autophagosomal membrane, which recruits proteins necessary for the biogenesis of the membrane-bound compartment. The lysosomal protein
Phaﬁn2, which contains PtdIns(3)P binding modules, associates with AKT to promote its lysosomal translocation. These observations suggest a model in which the intracellular spatial
regulation of AKT at lysosome affects autophagy induction: AKT targeted to the plasma membrane via PI(3,4,5)P3 inhibits autophagy, while AKT targeted to the lysosome via PtdIns(3)
P with Phaﬁn2 promotes autophagy.
348 M. Noguchi et al. / Biochimica et Biophysica Acta 1846 (2014) 342–352Given the above observations, it is clear that the relationship
between PI3K–AKT signaling and induction of autophagy is complex
(Table 1).
Pan-PI3K inhibitors, such as wortmannin and LY294002, are shown
to inhibit autophagy in isolated rat hepatocytes [78]. It is also reported
that an increase of class I PI3K products or stimulating enzymatic
activity of class I PI3K to produce class I PI3K products can reduce
macroautophagy [77]. In contrast, an increase in class III PI3K products
stimulates macroautophagy in human colon cancer HT-29 cells [77].Table 1
The roles of the PI3K–AKT–mTORC signal in the regulation of autophagy and
apoptosis.
The intracellular PI3K–AKT–mTOR signal is known to be important for the regulation of
cell survival. Accumulating evidence supported the direct involvement of the PI3K–AKT–
mTOR signal in the regulation of apoptosis and autophagy in mammalian cells. Class I
PI3K activation, but not class III PI3K activation, inhibited autophagy induction [77]. In
contrast, suppression of class I PI3K/class III PI3K inhibited autophagy induction [77].
Activation of AKT inhibits induction of autophagy [13,90], whereas dominant negative
AKT promoted autophagy [88–91]. Consistently, AKT/mTORC1 inhibitors promote both
apoptosis and autophagy [13,87]. It is well established that pan-PI3K inhibitors
(wortmannin or LY294002) are known to inhibit production of PI(3,4,5)P3, and hence
inhibit AKT kinase activity [1–3,32,75]. Therefore, full picture of the PI3K–AKT–mTOR
signal for the molecular regulation of apoptosis vs. autophagy is not completely clariﬁed.
Further studies will be required to fully understand the role of the PI3K–AKT–mTOR signal
and the additional signals that control the induction of autophagy vs apoptosis in different
cellular environment in mammalian cells.
Activity Apoptosis Autophagy
Class I PI3K ↑ ↓ ↓
↓ ↑ ↓
Class III PI3K ↑ ND ↑
↓ ↑ ↓
AKT ↑ ↓ ↓
↓ ↑ ↑
mTORC1 ↓ ↑ ↑The effect of class I PI3K inhibitors on autophagy is very context de-
pendent, partly because the speciﬁcity of inhibition of crossreactivity.
For example, class I PI3K products are known to activate AKT [13,90,
91] and thus likely to expect to block autophagy. Pan-PI3K inhibitors
inhibit production of PI(3,4,5)P3, and thereby block AKT kinase
activity [1–3,32,75]. Their usage would thus be expected to increase au-
tophagy. However, pan-PI3K inhibitors such as wortmannin and
LY294002 inhibit the production of not only PI(3,4,5)P3 but also
PtdIns(3)P [86], and therefore, it is logical that this would suppress
induction of autophagy.
The ability of class I and III inhibitors to block autophagy may be
linked to the AKT–Phaﬁn2 complex, since PtdIns(3)P-dependent lyso-
somal localization of the AKT–Phaﬁn2 complex is required for induction
of autophagy [28]. It is also plausible that class I PI3K products/activa-
tion to inhibit autophagy induction [77] is partly due to the conse-
quence of activation of AKT.
Although a prevailing view is that AKT activation blocks autophagy
[13,90,91], the elimination of AKTby siRNA can also paradoxically inhib-
it the process [28].
Furthermore, induction of AKT kinase activity is also stimulated by
the mTORC1 inhibitor [109,110], yet this compound robustly induces
autophagy [44,111,112]. In this scenario, induction of AKT in response
to mTORC1 inhibition is probably due to release of the feedback inhibi-
tion from mTORC1 towards PI3K e.g. via IRS1.
Presumably, the high levels of AKT phosphorylation in rapamycin-
treated cells may not be sufﬁcient to reverse the mTORC1 inhibition.
Notably, prolonged treatmentwith rapamycin inhibits AKT kinase activ-
ity [113], a ﬁnding supported by the presence of TSC-independent
mTORC2 regulation [114]. Thus, the precise effect of rapamycin treat-
ment in mammalian cells is heavily context-dependent.
Consistent with the role of mTOR in yeast, nutrition-dependent
regulation of mTOR is thought to be a major determinant of autophagy
inmammalian cells.mTORC1 is regulated through the activity of a class I
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AKT and PDK1, which subsequently blocks autophagy [7,84,85,101]. In
the absence of growth factors, mTOR is inactivated, which relieves its
inhibitory effect on autophagy. AKT inhibits the GTPase-activating pro-
tein complex TSC1–TSC2, leading to stabilization of RhebGTP, which
mediates signaling to mTOR, a key regulator of autophagy [84]. A TSC-
independent mechanism for autophagy regulation has also been pro-
posed [114].
In mammalian cells, hVps34 is also involved in nutrient signaling
tomTOR [82]. mTOR inhibition by starvation or rapamycin treatment
induces the recruitment of multiple Atg proteins to PAS (pre-autoso-
mal structures) to initiate autophagosome formation. Inactivation of
mTORC1 by rapamycin stimulates autophagy in the presence of nu-
trients, suggesting that mTOR blocks autophagy [115].
Recently, it was shown that TRAF6 together with p62 binds to
and induces K63-linked ubiquitination of mTOR [29] (Fig. 2). In this
scenario, mTOR ubiquitination by the p62–TRAF6 complex is central
to the regulation of cell growth, tumor transformation, and autophagy.
TRAF6 activates mTORC1 and inhibits autophagy through p62 and
the K63-linked polyubiquitination of mTOR [29,31]. Interfering with
mTOR ubiquitination or with the p62–TRAF6 interaction can impair
mTORC1 activation in response to nutrients, and has an important
impact on the control of cell proliferation and transformation [29].
Hence, TRAF6-mediated ubiquitination is important for the lysosomal
translocation and activation of mTORC1, which modulates autophagy
and nutrient sensing [29]. Recently, insulin stimulation and nutrient
signaling were shown to be critical for controlling the localization of
the mTOR and TSC complex at lysosomes [116].
8. Connection to cell death
There are three major types of cell death: apoptotic (type I cell
death), autophagic (type II cell death), and necrotic (type III cell
death) [117,118]. Autophagy is in some cases survival mechanism that
maintains the balance between themanufacture of cellular components
and the breakdown of damaged or unnecessary organelles and other
cellular constituents. However, autophagy also kills cells under certain
conditions, in a process called autophagic cell death; this involves path-
ways and mediators different from those of apoptosis [117,118]. In au-
tophagic cell death, cells die with an autophagic morphology and have
little or no association with phagocytosis, in contrast with apoptosis
[118]. Instead, a characteristic feature of autophagic cell death is the
appearance of vacuoles (autophagosomes) that are used for self-
degradation. Autophagic cell death appears to be accompanied by ‘clas-
sical’ autophagy, although it does not depend on this process [118].
Attention has turned to cross-talk regulation between anti-apoptotic
pathways and the induction of autophagy [7,117,119,120]. Given that
AKT signaling regulates the cell death and survival machinery, it will
be interesting to examine how AKT signaling integrates into the cell
death and survival machinery through autophagy. Proapoptotic signals
such as TRAIL (TNF-related apoptosis-inducing ligand) [121], TNF
(tumor necrosis factor) [122], and FADD (fas-associated protein with
death domain) [123] induce autophagy. Conversely, anti-apoptotic sig-
naling pathways such as the class I PI3K/AKT/mTOR axis suppress au-
tophagy [124]. Consistent with this notion, activation of AKT, a major
downstream effector of PI3K, which promotes cell survival, is an in-
hibitor of autophagy [7,13,90].
The precise nature of the cross-talk between cell death and survival
via AKT signaling remains undetermined. In one report, AKT inactiva-
tion with small molecule inhibitors did not appreciably induce apop-
tosis, but markedly increased autophagy [89]. It has been reported
that AKT and autophagy cooperate to promote the survival of drug-
resistant glioma. The combined inhibition of PI3K and mTOR with PI-
103 triggers autophagy without activating AKT (primarily in PTEN
mutant cells) [125]. Anti-apoptotic protein Bcl-2, a major effector of
AKT signaling that maintains the mitochondrial outer membranepotential to regulate the cell survival machinery, inhibits Beclin1-
dependent autophagy [126]. The autophagy protein Atg12 associates
with anti-apoptotic Bcl-2 family members to promote mitochondrial-
mediated apoptosis [111]. Autophagy induced by suberoylanilide
hydroxamic acid inhibits AKT and upregulates Beclin1 [127]. In
response to ceramide or starvation, the Beclin1 binding partner and in-
hibitor Bcl-2 are phosphorylated by JNK1 (c-Jun N-terminal kinase).
Hyperphosphorylated Bcl-2 dissociates from Beclin1, which is then
able to induce autophagy. In addition, phosphorylation of Beclin1 on
T119 by DAPK (death-associated protein kinase) also reduces the Bcl-
2–Beclin1 interaction and activates autophagy. Thus, phosphorylation
of autophagy-related proteins is an additional aspect of autophagy
regulation [6]. Notably, AKT regulates autophagy and tumorigenesis
through Beclin1 phosphorylation [11]. This may be due to AKT-
dependent regulation of the Beclin1/vimentin interaction, which mo-
dulates intermediate ﬁlament formation, the consequent suppression
of autophagy, and stimulates transformation.
FOXO3, a critical cell survival regulator downstream of AKT [105],
functions in parallel with the mTOR pathway through AKT to control
autophagy [6,107]. Phosphorylated FOXO3 controls the transcription
of autophagy-related genes including LC3 and Bnip3 (BNIP3 subfamily
of BH3-only proteins), whichmediates the effect of FOXO3 on autopha-
gy [128]. Activation of AKT induces Skp2/MDM2-mediated ubiquiti-
nation and proteasomal degradation of FOXO [129]. Furthermore, AKT
phosphorylates BAD, which subsequently increases the association of
BAD with 14-3-3 proteins, which prevents it from interacting with
the anti-apoptotic protein Bcl-2 [1–3]. Therefore, AKT–BAD–Bcl-2–
Beclin1–FOXO axis may underlie the regulation of autophagic versus
apoptotic cell death.
9. Concluding remarks
AKT signaling plays a central role in many biological processes in-
cluding cell proliferation and apoptosis. There is an increasing number
of AKT binding partners, each of which can modulate AKT activity [130,
131]. A series of studies has revealed a connection betweenAKT and two
important protein degradation pathways, ubiquitination and auto-
phagy. Upon growth factor stimulation, AKT translocates to the plasma
membrane via K63-linked ubiquitination. Thereafter, two critical ki-
nases mediate the activation of AKT: PDK1 phosphorylates AKT on
T308, and mTORC2 phosphorylates AKT on S473. SUMOlylation of AKT
by PIAS1 is also important for AKT activation anddownstreambiological
responses such as proliferation and tumorigenesis. In contrast, K48-
linked ubiquitination by BRCA1, TTC3, or MULAN primarily results in
the proteasomal degradation of AKT and thus silences AKT kinase activ-
ity. In addition to the ubiquitination of mTOR by TRAF6 and FOXO3 by
Skp2/MDM2 [6,29,129], several other ubiquitination substrates have
been identiﬁed, each of which is ﬁrmly at the intersection between
ubiquitination and autophagy [25,26]. The lysosomal localization of
AKT, which is regulated by the phosphatidylinositol [PtdIns(3)P]-
dependent localization of Phaﬁn2 to the lysosome, is an essential step
in the regulation of autophagy. It is plausible that during the course of
autophagy induction, AKT may phosphorylate autophagy regulatory
molecules at the lysosome. Casein kinase II, which is upstream of AKT
activation at the Golgi/lysosome [132], phosphorylates p62 at S403.
This phosphorylation regulates the selective autophagic clearance of
ubiquitinated proteins [30], perhaps as a failsafe mechanism for those
whichwere not efﬁciently degradedby proteasomes. Because activation
of AKT at the plasmamembrane inhibits the induction of autophagy, the
intracellular localization of AKT may affect the cellular responses of the
proteolytic cascade (Fig. 3).
Conjugation of K63-linked ubiquitin chains is important for AKT
membrane localization and oncogenic activation/phosphorylation.
Defects in K48-linked ubiquitination resulting from BRCA1 mutation,
for example, may enhance the overall activity of AKT. This directly im-
plicates AKT ubiquitination control as a critical step in its oncogenic
350 M. Noguchi et al. / Biochimica et Biophysica Acta 1846 (2014) 342–352activity. Since ubiquitination plays an important role in AKT activation,
we suggest that small molecule inhibition of this pathway is an attrac-
tive strategy for treatment of human diseases. For example, an inhibitor
of K63-linked AKT ubiquitination should inhibit plasma membrane
recruitment of AKT and block its activation. Alternatively, activation of
TTC3 or other ligases that mediate K48-linked ubiquitination of AKT
could also inhibit the kinase. Overall, the ﬁnding that AKT signaling
contributes to the regulation of autophagy and ubiquitination offers
new therapeutic targets for humandiseases causedby the dysregulation
of autophagy such as infection, cancer, and neurodegenerative diseases.Acknowledgement
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